Oruka Therapeutics, Inc.
ORKA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ORKA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ORKA
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for immune-mediated diseases, with a lead program in Phase 2 and a cash runway extending beyond twelve months.
Key risk: No approved products or revenue
BioSniper Score
Based on 6 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 7 clinical trials · 3 catalysts for Oruka Therapeutics, Inc..
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for immune-mediated diseases, with a lead program in Phase 2 and a cash runway extending beyond twelve months.
- Cash, cash equivalents, and marketable securities of $1.1 billion as of June 30, 2026 [sec_mda].
- Net loss of $41.2 million for the three months ended June 30, 2026, and accumulated deficit of $262.2 million as of that date [sec_mda].
- Lead product candidate orka-001 is in Phase 2 clinical trials, with topline data expected by the end of 2026 [catalyst].
- The company has not yet commercialized any products and does not expect to generate product revenue for several years, if at all [sec_mda].
- In April 2026, the company raised $700.4 million in gross proceeds from an underwritten public offering [sec_mda].
What works
- Substantial cash position of $1.1 billion as of June 30, 2026, expected to fund operations for at least twelve months [sec_mda].
- Multiple Phase 2 readouts for orka-001 and orka-002 are scheduled through 2027, providing potential catalysts [catalyst].
- Access to an at-the-market equity offering program of up to $200 million, providing additional financial flexibility [sec_mda].
What to weigh
- Significant operating losses and negative cash flow from operations, with a net loss of $73.0 million for the six months ended June 30, 2026 [sec_mda].
- Accumulated deficit of $262.2 million as of June 30, 2026, with losses expected to increase as clinical development progresses [sec_mda].
- No approved products or revenue, and the company will need additional financing to complete development and commercialization [sec_mda].
- Clinical development is inherently unpredictable, with risks related to trial enrollment, completion, and regulatory approval [sec_mda].
From the filings
Quoted directly from source documents.
Cash position as of June 30, 2026
“We had cash, cash equivalents, and marketable securities of $1.1 billion as of June 30, 2026.”
SEC MD&A · August 10, 2026
Net loss for the three months ended June 30, 2026
“For the three and six months ended June 30, 2026, we had net losses of $41.2 million and $73.0 million, respectively”
SEC MD&A · August 10, 2026
Accumulated deficit as of June 30, 2026
“As of June 30, 2026, we had an accumulated deficit of $262.2 million.”
SEC MD&A · August 10, 2026
Cash runway expectation
“We expect that our existing cash, cash equivalents, and marketable securities will be sufficient to fund our operating plans for at least twelve months from the date of filing of this Quarterly Report.”
SEC MD&A · August 10, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · orka-001 — Phase 2 Readout: orka-001 — Topline data from the Phase 2 trial of orka-001 are expected by the end of 2026.
- 2027-12-31 · Phase2_Topline · orka-001 — Phase 2 Readout: orka-001 — Additional Phase 2 readout for orka-001 is anticipated in 2027.
- 2027-12-31 · Phase2_Topline · orka-002 — Phase 2 Readout: orka-002 — Topline data from the Phase 2 trial of orka-002 are expected in 2027.
Risks & what to watch (4)›
Key risks
- No approved products or revenue — The company has not commercialized any products and does not expect to generate product revenue for several years, if at all [sec_mda].
- Need for future financing — The company will need additional financing to fund research, development, and commercialization; lack of liquidity could have a material adverse effect [sec_mda].
- Clinical development uncertainty — Success depends on timely completion of preclinical studies and clinical trials, effective IND applications, and regulatory approvals [sec_mda].
- Increasing operating losses — Losses are expected to increase in absolute terms as the company continues clinical development and prepares for potential commercialization [sec_mda].
What to watch
- Topline Phase 2 data for orka-001 expected by the end of 2026 [catalyst].
- Topline Phase 2 data for orka-001 and orka-002 expected in 2027 [catalyst].
- Cash burn rate and any additional financing activities, including use of the ATM program [sec_mda].
- Progress in enrolling and completing ongoing clinical trials [sec_mda].
Sources: SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Oruka Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Oruka Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
76.6 months
D/E 0.02
Lead: Phase 2
3 candidates
3 upcoming, next in ~123d
0 buys · 69 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
182
Total value held
$2.36B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 7,431,403 | $364.5M |
| vanguard capital management llc | 3,719,262 | $182.4M |
| blackrock, inc. | 3,527,087 | $173.0M |
| remedium capital partners, llc | 3,454,776 | $169.5M |
| perceptive advisors llc | 2,791,002 | $136.9M |
| viking global investors lp | 2,666,690 | $130.8M |
| rtw investments, lp | 2,058,148 | $101.0M |
| deep track capital, lp | 2,034,203 | $99.8M |
| avidity partners management lp | 1,520,848 | $89.3M |
| state street corp | 1,613,461 | $79.1M |
Showing top 10 of 182 institutional holders of Oruka Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 17.9%
- Days to cover
- 3.5
- Shares short
- 6,992,310
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ORKA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Oruka Therapeutics, Inc.?
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for immune-mediated diseases, with a lead program in Phase 2 and a cash runway extending beyond twelve months.
What is Oruka Therapeutics, Inc.'s next catalyst?
Oruka Therapeutics, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: orka-001" — expected December 31, 2026.
Who is the CEO of Oruka Therapeutics, Inc.?
Dr. Lawrence Otto Klein Ph.D. is the chief executive officer of Oruka Therapeutics, Inc. (ORKA).
Where is Oruka Therapeutics, Inc. headquartered?
Oruka Therapeutics, Inc. (ORKA) is headquartered in Menlo Park, CA, United States.
What therapeutic areas does Oruka Therapeutics, Inc. focus on?
Oruka Therapeutics, Inc. develops therapies across Immunology, Cardiovascular, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.